Table 3.
Stimulation indices of PBMCs from normal donors, BD patients, non BD group and control diabetic patients who had retinal damage due to photocoagulation.
| P1 = 20 µg/ml | P2 = 20 µg/ml | P3 = 20 µg/ml | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sl no. | NL | BD | UV | DM/PHC | NL | BD | UV | DM/PHC | NL | BD | UV | DM/PHC |
| 1 | 1·2 | 1·6 | 1·3 | 1·1 | 1·2 | 1·8 | 1·2 | 0·7 | 0·9 | 1·2 | 1·3 | 0·6 |
| 2 | 1·1 | 1·3 | 1·9 | 0·9 | 1 | 1 | 1·3 | 0·9 | 0·8 | 1 | 1·8 | 0·9 |
| 3 | 1·8 | 1·1 | 2·1 | 1·0 | 1·8 | 1·3 | 2·9 | 1·1 | 2·4 | 1·1 | 2·1 | 1·1 |
| 4 | 0·9 | 3 | 2 | 1·1 | 1 | 0·9 | 2·3 | 1·1 | 0·2 | 1·2 | 2 | 1·0 |
| 5 | 0·8 | 3·5 | 1·7 | 1·1 | 0·5 | 1·9 | 1·2 | 0·6 | 1 | 1·4 | 1·7 | 2·0 |
| 6 | 1·5 | 2·9 | 1·2 | 0·3 | 1·1 | 8·7* | 2·3 | 0·5 | 1 | 9·8* | 1·2 | 0·3 |
| 7 | 0·3 | 0·7 | 0·6 | 0·3 | 0·2 | 1·9 | 1·9 | 0·2 | 1·7 | 0·7 | 0·9 | 0·2 |
| 8 | 1 | 0·7 | 0·7 | 0·7 | 2·9 | 13·2* | 2·3 | 1·1 | 0·6 | 1·2 | 0·7 | 1·0 |
| 9 | 1·9 | 0·6 | 0·9 | 1·1 | 2·3 | 0·4 | 3 | 1·3 | 1·7 | 0·6 | 0·9 | 1·4 |
| 10 | 0·9 | 7·5* | 1·4 | 1·5 | 3·3 | 2·8 | 0·8 | 5·7* | 1·4 | |||
| 11 | 1·5 | 2·9 | 1·9 | 1·5 | 1·8 | 3 | 2·3 | 2·2 | 1·9 | |||
| 12 | 2 | 14·1* | 1·6 | 1·9 | 5·7* | 3·5 | 2·9 | 9* | 1·6 | |||
| 13 | 1·7 | 2·1 | 0·5 | 2·2 | 2 | 0·5 | 1·65 | 2·1 | 0·7 | |||
| 14 | 1·3 | 3·9 | 0·4 | 1·1 | 2·7 | 0·8 | 1·4 | 4·6 | 1·0 | |||
| 15 | 3·4 | 1·5 | 1·2 | 3·1 | 3 | 1·2 | 2·7 | 3·1 | 1·2 | |||
| 16 | 2·1 | 1·3 | 0·4 | 1·7 | 2·4 | 0·8 | 1·3 | 3·1 | 1·2 | |||
| 17 | 1 | 0·9 | 1·2 | 0·7 | 1 | 1·9 | 0·6 | 1·2 | 2·1 | |||
| 18 | 1·3 | 1 | 0·7 | 1·1 | 2·5 | 1·0 | 1·01 | 4·1 | 0·9 | |||
NL, healthy controls; BD, Behcets disease group; UV, other uveitis (non BD group); DM/PHC, control diabetic patients who had retinal damage due to photocoagulation. P1, P2 and P3 are the three Tropomyosin derivative peptides.
*
indicates significant proliferative responses in BD patients compared with disease well as healthy controls (P < 0·02).